BridgeBio Pharma's Q2 revenue beats on higher Attruby sales
BBIO•Overview
- US biopharma firm's Q2 revenue more than doubled yr/yr, beating analyst expectations
- Company posted a narrower net loss per share compared to Q2 last yr
- BridgeBio closed $1 bln preferred equity financing after quarter-end
Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q2 Revenue | Beat | $243.68 mln | $218.74 mln (17 Analysts) |
| Q2 Loss Per Share | $0.78 | ||
| Q2 Net Loss | $155.89 mln | ||
| Q2 Operating Income | -$107.08 mln |
Result Drivers
- ATTRUBY SALES - Revenue growth was mainly driven by higher U.S. sales of Attruby, led by increased use in treatment-naïve patients
- ROYALTY REVENUE - Higher royalty revenue, mainly from BEYONTTRA sales in the EU and Japan, contributed to revenue growth
- OPERATING EXPENSES - Operating costs rose due to continued investment in commercialization of Attruby and pre-commercial activities for late-stage pipeline products
